Featured
Markets wobble on geopolitical nerves, but Precision Funds’ Dermot Woods and Andy Clayton still find three resources plays worth backing.
Geopolitical jitters continue to weigh on the ASX healthcare sector, even as LTR Pharma advances its erectile dysfunction trial and Neuren’s partner pushes back on Europe’s rejection of its Rett syndrome drug.
Wolfe Energy has launched a $7 million IPO at 20c per share, chasing a slice of the US uranium market via an historic high-grade prokect.
As markets adjust to the prospect of a drawn-out conflict in the Middle East, fund managers share the stocks they are backing.
